Objective: To evaluate the effect of multimicronutrient supplementation for undernourished pregnant women on the birth size of their offspring, incidence of lowbirth-weight infants (Ͻ2500 g), and early neonatal morbidity.
L
OW BIRTH WEIGHT (LBW) (Ͻ2500 g) is a major predictor of neonatal and infant mortality. 1 Intrauterine growth retardation, rather than prematurity, is the principal cause of LBW in South Asian countries. 2 Infants who are small or disproportionate in size at birth also have an increased risk of developing coronary heart disease, type 2 diabetes mellitus, stroke, and hypertension during adult life. It is postulated that these diseases are programmed by inadequate supply of nutrients to the developing fetuses (the Barker hypothesis). 3 Thus, measures to increase the size of infants at birth constitute a priority area in developing nations.
Prepregnancy and maternal undernutrition are important predictors of reduced birth weight in resource-poor settings. 1, 2, 4 It now appears that several nutrient factors, including both macronutrients and micronutrients, may be deficient in mothers in developing countries. 5, 6 The habitual diet of women be-
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longing to low-income groups is deficient not only in calories and proteins but also in vitamin C, vitamin E, folate, vitamin B complex, and trace elements such as iron, zinc, magnesium, manganese, and selenium. In a study of 513 pregnancies in Hackney, England, Doyle et al 7 reported that mothers who subsequently gave birth to LBW infants had low intake of 43 of 44 nutrients, including copper, zinc, magnesium, vitamin A, vitamin C, vitamin E, and vitamin B complex. Another study of rural Indian women documented a strong relationship between infant birth weight and the mother's intake of foods rich in micronutrients, suggesting that these may be important limiting factors for fetal growth in undernourished mothers. 5 Compared with iron and folic acid supplementation, community-based studies in Nepal 8 and Mexico 9 have failed to document an increase in birth weight or a decline in the incidence of LBW after antenatal multimicronutrient supplementation. On the other hand, recent trials conducted by Osrin et al 10 in Nepal and Kaestel et al 11 in Guinea-Bissau demonstrated an increase in the birth size with antenatal multimicronutrient supplementation. Friis et al 12 conducted another randomized trial in Zimbabwe and concluded that antenatal multimicronutrient supplementation may be one strategy to increase birth size, although their results failed to achieve a statistically significant difference. However, these trials did not selectively target undernourished pregnant women who are at greater risk for delivering infants with lower birth size. We therefore evaluated the effect of multimicronutrient supplementation in undernourished pregnant women on birth size and early neonatal morbidity.
METHODS
The study was designed as a randomized, double-blind, placebocontrolled trial conducted in a tertiary care hospital of East Delhi, India, from May 1, 2002 , to April 30, 2003 . The hospital serves poor residents living in nearby urban slums and families from surrounding rural communities. A clearance was obtained from the ethical committee of the Sitaram Bhartia Institute of Science and Research, New Delhi, India. The study protocol was fully explained to the participants, and informed signed consent was obtained.
ENROLLMENT
The sample size was calculated from a community-based, longitudinal study of pregnant rural Indian women correlating the intake of micronutrient-rich foods with the birth weight of their offspring. 5 A total of 100 women in each group were required to detect a difference of 150 g in mean birth weights (estimated SD, 350 g for each group) with a significance level of .05 and a power of 80% after allowing for a 20% loss to followup. Thus, we enrolled 200 pregnant women (age range, 18-44 years) of any gravidity with a period of gestation ranging from 24 to 32 weeks, carrying a singleton pregnancy, and having a body mass index (calculated as weight in kilograms divided by the square of height in meters) of less than 18.5 and/or a hemoglobin level of 7 to 9 g/dL from our antenatal clinic (Figure 1) . Only women residing within 5 km of the hospital and planning to deliver in the hospital or in the neighborhood were enrolled. Women with the following established medical risk factors for having reduced or excessive birth weight of the neonate were excluded: hypertension, renal disease, heart disease, diabetes mellitus, urinary tract infection, tuberculosis, smoking, alcohol intake, or chronic intake of other drugs. Women already receiving iron and folic acid or other micronutrient tablets were also excluded.
INITIAL DATA COLLECTION
Baseline data collected included name, age, address, telephone number, religion, education, occupation, obstetric history, parity, family income, and the number of family members. Gestational age was calculated by last menstrual period and clinical evaluation. The woman's typical daily activity was recorded as domestic or outdoor. Prepregnancy weight was obtained by checking the previous health records or by recall. Present weight was recorded on a standardized bathroom scale to the nearest 0.5 kg. Height was measured to the nearest 0.1 cm. The body mass index was calculated by dividing the prepregnancy weight in kilograms by the square of the height in meters. Hemoglobin levels were measured using the Sahli method and recorded in grams per deciliter. The same observer (M.R.) obtained all of the measurements.
RANDOMIZATION AND BLINDING
Participants were randomized to receive the multimicronutrient supplementation (micronutrient group) or the placebo (pla- cebo group) from 24 to 32 weeks of gestation onward. Allocation was based on a 2-step simple randomization. Subjects were first allocated (by computer-generated random sequence) to be in 1 of 10 blocks of 20 subjects each. These blocks were coded as 1 to 10 in a random manner. Of 1 to 10, 5 blocks were randomly assigned to receive the placebo and the rest to receive the multimicronutrient tablets. Tablets were kept in containers marked 1 to 10. A participant received the drug from 1 of these 10 containers per allocation. Allocation was concealed by the use of sealed envelopes. The caregiver and the subject were blinded regarding the content of the tablet being given. Randomization, coding, allocation concealment, and blinding was performed by one of us (R.K.), and the drugs were dispensed by another (M.R.). The multimicronutrient tablet contained the following: beta carotene (vitamin A), concentrated in 2500 IU; thiamine mononitrate (vitamin B 1 ), 1 mg; riboflavin (vitamin B 2 ), 1.5 mg; pyridoxine hydrochloride (vitamin B 6 ), 1 mg; cyanocobalamin (vitamin B 12 ), 1 µg; ascorbic acid (vitamin C), 50 mg; cholecalciferol (vitamin D 3 ), 200 IU; tocopherol acetate (vitamin E), 7.5 mg; calcium pantothenate, 5 mg; folic acid, 0.15 mg; nicotinamide (niacinamide), 20 mg; biotin, 30 µg; zinc, 15 mg; potassium iodide, 0.15 mg; ferrous fumarate, 10 mg; magnesium oxide (light), 100 mg; manganese sulfate, 2.5 mg; copper, 2 mg; calcium, 162 mg; phosphorus, 125 mg; potassium, 40 mg; chloride, 36.3 mg; chromium, 25 µg; molybdenum, 25 µg; sodium selenate, 30 µg; nickel, 5 µg; silicon dioxide, 2 mg; vanadium, 10 µg; and boron, 150 µg. The placebo tablet consisted of calcium with chocolate flavor and color.
The supplement and the placebo looked and tasted alike. Participants and the physicians were unaware of group allocation. The code key was opened only after the intervention, data collection, follow-up, and tabulation were finished.
INTERVENTION
Pregnant women were advised to take the supplement once a day, 30 minutes after meals. Tablets were given to the participants on a fortnightly basis and they were asked to maintain a record of tablet consumption. All participants were advised concerning a proper diet (based on the Indian Council of Medical Research recommendation for pregnant women), 13 administered iron (given in the form of ferrous sulfate, containing 60 mg of elemental iron) and folic acid supplements in the usual dosages, ie, 60 mg/d and 500 µg/d, respectively, and given routine antenatal advice, immunization, and health education. Supplementation continued until delivery. At each antenatal visit, the participants were questioned regarding tablet intake, compliance, and adverse effects. The number of tablets consumed was cross-checked by observing the remaining number of tablets in each pack. Compliance was defined as the percentage of tablets consumed by each participant compared with the number of days the drug was advised to be taken.
CLINICAL MONITORING
Clinical monitoring was performed during each antenatal visit, eg, every 4 weeks until 36 weeks of gestation and then weekly until delivery. Maternal weight gain was recorded. The presence of edema, gestational hypertension, preeclampsia, antepartum hemorrhage, fever, urinary tract infection, preterm labor, premature rupture of membranes, diarrhea, gestational diabetes, drug intake, and any decrease in fetal movements was recorded. If the participant failed to appear within 1 week of her expected antenatal follow-up, she was contacted by mail or by telephone. All clinical decisions regarding management, timing of delivery, etc, were made by the attending faculty and
FINAL DATA COLLECTION AT DELIVERY
All efforts were made to have the mother deliver at the hospital. The date and time of delivery, maternal weight and gestational age at delivery, mode of delivery, and any complications during or after delivery, including premature rupture of membranes, antepartum hemorrhage, preeclampsia, toxemia, fetal distress, birth asphyxia, and meconium staining, were recorded. In case of home delivery, the mother was contacted personally and details regarding the delivery were obtained.
NEONATAL CHARACTERISTICS
Gestational age was calculated using the new Ballard score.
14 Apgar scores were recorded in hospital deliveries. The newborn was labeled according to gestational age as term (37-41 weeks), preterm (Ͻ37 weeks), or post term (Ն42 weeks). Birth weight was recorded within 30 minutes for institutional deliveries and at the first contact after birth (within 3 days) for home deliveries. An electronic weighing scale (Seca, Hamburg, Germany) was used to record the weight to the nearest 5 g. Neonatal crown-to-heel length was measured to the nearest 0.1 cm using an infantometer, with the infant supine, the neck fully extended, the soles of feet held firmly against the footboard, and the head touching the fixed board. Midarm circumference was measured to the nearest 0.1 cm in the left upper arm, midway between the acromion and olecranon processes. A standardized fiberglass tape was used. Neonates weighing less than 2500 g were designated as LBW, irrespective of gestation. In addition, they were classified as being small (SGA), appropriate, or large for gestational age according to the chart of intrauterine growth by Lubchenco et al. 15 Newborns delivered at the hospital were followed up for the first 7 days to document any evidence of congenital anomaly, sepsis (clinically suspected or culture proved), respiratory distress (respiratory rate of Ͼ60/min, retractions, or grunt), diarrhea, vomiting or abdominal distention, jaundice, convulsions, bleeding, hypothermia, skin boils, and any other morbidity. Standard definitions based on the recommendations of the National Neonatology Forum of India were used for defining neonatal morbidities. 16 In case of death of the newborn, the most probable cause of death was recorded per the attending clinician's diagnosis. Those women who delivered at home were asked for any history of neonatal illness, clinic visit, or hospitalization during the first week after birth. The cause of death was ascertained by verbal autopsy.
STATISTICAL ANALYSIS
Data were analyzed on an intention-to-treat basis. 17 Birth weight was the primary outcome variable. Secondary outcome measures included length and midarm circumference at birth, incidence of LBW and SGA infants, and early neonatal morbidity. Baseline variables and outcome measures were compared by the unpaired t test for continuous variables and the 2 test or the Fisher exact test for categorical variables. To assess between-group differences, multiple regression analysis was performed for continuous dependent variables (ie, birth weight, length, and midarm circumference). Logistic regression analysis was used when the dependent variable was dichotomous, ie, incidence of LBW, SGA, and early neonatal 
RESULTS
Two hundred undernourished pregnant women were included in the trial after providing written informed consent ( Figure 1 ). Participants were randomized to receive multimicronutrient supplementation (n = 99) or placebo (n = 101). Baseline characteristics of the enrolled subjects were comparable in both groups ( Table 1) . Subjects in the micronutrient group received supplementation for a mean (SD) duration of 54.5 (27.6) days (median, 58 days; interquartile range, 37-77 days) compared with the placebo group, who received the drugs for a mean (SD) duration of 45.1 (29.4) days (median, 52 days; interquartile range, 15-66 days) (P = .02). The actual duration of supplementation in the 2 groups is shown in Table 2 . Median compliance in the micronutrient and placebo groups was 87% and 85%, respectively. Adverse effects of the supplementation (nausea, vomiting, diarrhea, abdominal pain, and anorexia) were seen in 7 subjects in the micronutrient group and 13 in placebo group. None of the adverse effects necessitated discontinuation of supplementation.
Complications of pregnancy occurred in 3 subjects in the micronutrient group and 4 in the placebo group (P = .71). Pregnancy-induced hypertension was detected in a total of 5 women, including 2 in the micronutrient group and 3 in the placebo group. Infections (ie, urinary tract, tuberculosis, or respiratory tract) were documented in 1 subject in the micronutrient group and 2 in the placebo group. Women in the micronutrient group gained a mean (SD) weight of 9.2 (2.8) kg during pregnancy compared with 8.7 (2.9) kg in the placebo group (P=.26). The mean (SD) gestational ages at delivery were 39.6 (1.4) and 39.6 (1.4) weeks in the micronutrient and placebo groups, respectively (P =.9).
Delivery details were available for 170 cases. Of these, 134 (78.8%) delivered in the hospital, whereas 36 (21.2%) delivered at home. Of these 170 infants, 45 (51%) of 88 in the micronutrient group and 42 (51%) of 82 in the placebo group were boys. The proportion of home deliveries was also comparable in both groups (micronutrient group, 20 [23%]; placebo group, 16 [19%] ; P=.71). Only 5 women required assisted or operative intervention during delivery (3 in the micronutrient group and 2 in the placebo group). Complications of delivery were present in 13 (15%) of 88 cases in the micronutrient group compared with 10 (12%) of 82 in the placebo group (P=.66). Birth weight and details of morbidity in the first week of life were available for 146 and 170 neonates, respectively. A comparison of baseline variables between those available (n = 146) and those lost to follow-up (n = 54) revealed that women who dropped out of the study had a lower family income (mean [SD], 2972 [1070] Abbreviation: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared). *Unless otherwise indicated, data are expressed as mean (SD). The birth weights ranged from 750 to 3500 g. Only 2 infants were preterm (gestational ages, 32 and 31 weeks) and weighed 750 and 950 g, respectively (1 infant in each group). The distribution of birth weights between the micronutrient and placebo groups is provided in Figure 2 . After adjusting for 8 potential confounding factors, birth weight in the micronutrient group was 98 g (range, −16 to 213 g) higher than in the placebo group; the effect size was small with a wider confidence interval. Neonates in the micronutrient group measured 0.8 cm longer and 0.2 cm larger in midarm circumference ( Table 3 ). The proportion of LBW infants decreased by 70% in the micronutrient group. The proportion of SGA infants also decreased by 55% in the micronutrient group (Table 3) . Furthermore, multiple regression analysis in the micronutrient group showed that the duration of multimicronutrient supplementation and compliance demonstrated a significant positive correlation with birth size (Table 4) . Women who were anemic (using the World Health Organization cutoff for hemoglobin level of 11 g/dL in pregnant women) were not likely to benefit more from multimicronutrient supplementation, in terms of birth size. Also, there was no significant difference between birth size for women with hemoglobin levels of less than 9 g/dL and the rest in the micronutrient group (data not shown).
Morbidities were present in 36 (21.2%) of 170 neonates during the first week of life. The total number of illnesses was 41 because some neonates had more than 1 illness. The number of illnesses in the micronutrient and placebo groups was 15 (sepsis, 11; others, 4) and 26 (sepsis, 19; others, 7), respectively. The incidence of early neonatal morbidity was almost double in the placebo group compared with the micronutrient group (Table 3) . Birth weight correlated very strongly with neonatal morbidity when included in the multivariate model, eliminating the group effect (PϽ.001). A total of 8 infants died, 4 in each group (relative risk, 0.93; 95% confidence interval, 0.24-3.61; P=.92). Causes of death were similar in the 2 groups and included sepsis in 4 and asphyxia/ intracranial bleeding in the rest.
COMMENT
We examined the effect of multimicronutrient supplementation in pregnant undernourished women on the birth size of their infants and the incidence of LBW in a hospital-based study in a setting where the incidence of LBW is more than 30%. 1 We concluded that multimicronutrient supplementation targeted at pregnant undernourished women may decrease the incidence of LBW infants, despite no statistically significant change in birth weight. This translated into significantly lower neonatal illnesses during the first week of life in the micronutrient group. There was no effect on the duration of gestation.
The major strength of the present study was its focused approach. Supplementation was restricted to a relatively homogeneous group of undernourished pregnant women from an urban poor population who are likely to show the maximum benefit of such an intervention. Limitations include a large loss to follow-up (27.0%), limited power of the study to detect small changes in birth size, and the lack of data on late neonatal morbidity and perinatal mortality. The study population from urban slums is migratory, and it is typical for them to change homes, 1 9 0 0 -2 0 9 9 2 1 0 0 -2 2 9 9 2 3 0 0 -2 4 9 9 2 5 0 0 -2 6 9 9 2 7 0 0 -2 8 9 9 2 9 0 0 -3 0 9 9 3 1 0 0 -3 2 9 9 3 3 0 0 -3 4 9 9
Birth Weight, g Frequency Figure 2 . Bihistogram depicting distribution of birth weights in the micronutrient and placebo study groups. Abbreviations: CI, confidence interval; LBW, low-birth-weight (Ͻ2500 g); SGA, small for gestational age. *Calculated as the difference between study groups. †Calculated as the relative risk between study groups. ‡Adjusted for maternal age, family income, parity, prepregnancy weight, height, hemoglobin, neonatal sex, and gestational age at delivery. §Gestational age at delivery was replaced by birth weight as an independent variable when the dependent variable was gestational age. 
